PPARG and juvenile Huntington disease: Protective effects have been seen with PPARγ agonists in murine models of Alzheimer's disease (Escribano et al., 2009), Parkinson's disease (PD) (Dehmer et al., 2004; Breidert et al., 2002; Schintu et al., 2009; Carta et al., 2011), amyotrophic lateral sclerosis (Kiaei et al., 2005), Huntington's disease (Quintanilla et al., 2008) and multiple sclerosis (Feinstein et al., 2002; Niino et al., 2001).